SG161217A1 - New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents - Google Patents
New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agentsInfo
- Publication number
- SG161217A1 SG161217A1 SG201002269-7A SG2010022697A SG161217A1 SG 161217 A1 SG161217 A1 SG 161217A1 SG 2010022697 A SG2010022697 A SG 2010022697A SG 161217 A1 SG161217 A1 SG 161217A1
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- heterocyclic compounds
- medicaments
- new heterocyclic
- alzheimer agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
- C07D215/34—Carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05290719 | 2005-04-01 | ||
| EP05290914A EP1731507A1 (en) | 2005-04-26 | 2005-04-26 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG161217A1 true SG161217A1 (en) | 2010-05-27 |
Family
ID=36590178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201002269-7A SG161217A1 (en) | 2005-04-01 | 2006-03-29 | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7977354B2 (da) |
| EP (1) | EP1868998B1 (da) |
| AU (1) | AU2006228683B2 (da) |
| CA (1) | CA2603345C (da) |
| DK (1) | DK1868998T3 (da) |
| IL (1) | IL186233A (da) |
| NZ (1) | NZ561953A (da) |
| SG (1) | SG161217A1 (da) |
| WO (1) | WO2006103120A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| EP2350010B1 (en) * | 2008-10-30 | 2014-03-26 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
| WO2012087872A1 (en) | 2010-12-23 | 2012-06-28 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as crth2 receptor modulators |
| MX2013007295A (es) | 2010-12-23 | 2013-08-26 | Merck Sharp & Dohme | Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2. |
| US8946261B2 (en) | 2011-02-14 | 2015-02-03 | Council Of Scientific & Industrial Research | Substituted 1, 2, 3, 4-tetrahydroquinolin-7-yl carbamates as acetylcholinesterase inhibitors for treatment of Alzheimer's disease |
| WO2014113495A1 (en) * | 2013-01-15 | 2014-07-24 | The Trustees Of Columbia University In The City Of New York | Activation or reactivation of ache |
| EP2759536A1 (en) | 2013-01-25 | 2014-07-30 | INSA (Institut National des Sciences Appliquees) de Rouen | Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| CN105622501B (zh) * | 2016-03-30 | 2019-02-19 | 皖南医学院 | N-芳基-3-碘代喹啉衍生物及其制备方法 |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| UA126119C2 (uk) * | 2016-11-11 | 2022-08-17 | Баєр Енімал Хелс Гмбх | Протигельмінтні похідні хінолін-3-карбоксаміду |
| KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE892088L (en) * | 1988-07-12 | 1990-01-12 | William Henry Deryk Morris | Quinoline derivatives, their production and use |
| US5714615A (en) | 1994-02-08 | 1998-02-03 | Georgia Tech Research Corporation | Pyridinium compounds |
| IL115113A (en) | 1995-08-31 | 2002-11-10 | Israel State | 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them |
| PT1397364E (pt) | 2001-05-24 | 2007-10-22 | Lilly Co Eli | Novos derivados de pirrole como agentes farmacêuticos |
-
2006
- 2006-03-29 WO PCT/EP2006/003787 patent/WO2006103120A2/en active Application Filing
- 2006-03-29 EP EP06742673.4A patent/EP1868998B1/en active Active
- 2006-03-29 DK DK06742673.4T patent/DK1868998T3/da active
- 2006-03-29 AU AU2006228683A patent/AU2006228683B2/en not_active Ceased
- 2006-03-29 CA CA2603345A patent/CA2603345C/en not_active Expired - Fee Related
- 2006-03-29 NZ NZ561953A patent/NZ561953A/en not_active IP Right Cessation
- 2006-03-29 SG SG201002269-7A patent/SG161217A1/en unknown
- 2006-03-29 US US11/909,911 patent/US7977354B2/en not_active Expired - Fee Related
-
2007
- 2007-09-24 IL IL186233A patent/IL186233A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1868998B1 (en) | 2016-05-25 |
| WO2006103120A2 (en) | 2006-10-05 |
| US20090062279A1 (en) | 2009-03-05 |
| IL186233A (en) | 2012-07-31 |
| EP1868998A2 (en) | 2007-12-26 |
| DK1868998T3 (da) | 2016-08-29 |
| WO2006103120A3 (en) | 2007-02-15 |
| AU2006228683B2 (en) | 2012-02-02 |
| AU2006228683A1 (en) | 2006-10-05 |
| CA2603345C (en) | 2017-05-02 |
| NZ561953A (en) | 2011-11-25 |
| US7977354B2 (en) | 2011-07-12 |
| IL186233A0 (en) | 2008-01-20 |
| CA2603345A1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG161217A1 (en) | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents | |
| WO2005111002A3 (de) | Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
| WO2004075864A3 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| MXPA06011194A (es) | Tiadiazolidinonas como inhibidores de gsk-3. | |
| DE602004028150D1 (de) | Aminopyrazolderivate als gsk-3-inhibitoren | |
| MX2008002061A (es) | Derivados de tiazolil piperidina utiles como moduladores del receptor h3. | |
| MX2010009752A (es) | Compuestos de oxadiazoantraceno para el tratamiento de diabetes. | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| ATE499372T1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
| TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them | |
| WO2006055434A3 (en) | Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| PL1809288T3 (pl) | Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
| SE0400043D0 (sv) | New compounds | |
| DE602008004540D1 (de) | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydroindolizin-3-yl)acetamidderivate und verwandte verbindungen als antipilzmittel | |
| TW200740781A (en) | Novel compounds | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
| WO2008056266A8 (en) | Substituted 8-piperidinyl-2-pyridinyl-pyrimido [1,2-a]pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a]pyrimidin-6-one derivatives |